Cargando…
Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study
BACKGROUND: The optimal chemotherapeutics of recurrent disseminated glioblastoma has yet to be determined. We analyzed the efficacy and safety of recombinant human endostatin (rh-ES) combined with temozolomide and irinotecan in patients with recurrent disseminated glioblastoma. METHODS: We retrospec...
Autores principales: | Ge, Jing-jing, Li, Cheng, Qi, Shao-pei, Xue, Feng-jun, Gao, Zhi-meng, Yu, Chun-jiang, Zhang, Jun-ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6950828/ https://www.ncbi.nlm.nih.gov/pubmed/31914946 http://dx.doi.org/10.1186/s12885-019-6467-6 |
Ejemplares similares
-
Recombined humanized endostatin‐induced suppression of HMGB1 expression inhibits proliferation of NSCLC cancer cells
por: Meng, Fan‐Jie, et al.
Publicado: (2018) -
An Endostatin-lentivirus (ES-LV)-EPC gene therapy agent for suppression of neovascularization in oxygen-induced retinopathy rat model
por: Ai, Jing, et al.
Publicado: (2020) -
Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018) -
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016) -
Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)